A Phase II Study With A Safety Lead-In Of Nivolumab In Combination With Bevacizumab For The Treatment Of Relapsed Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer

Trial Profile

A Phase II Study With A Safety Lead-In Of Nivolumab In Combination With Bevacizumab For The Treatment Of Relapsed Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Nivolumab (Primary) ; Bevacizumab
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 27 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 24 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top